{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:20:30Z","timestamp":1771266030922,"version":"3.50.1"},"reference-count":58,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST109-2320-B-075-002"],"award-info":[{"award-number":["MOST109-2320-B-075-002"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST110-2320-B-075-007"],"award-info":[{"award-number":["MOST110-2320-B-075-007"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2320-B-075-004"],"award-info":[{"award-number":["MOST 111-2320-B-075-004"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Clinical trials have investigated the role of antiresorptive agents, including bisphosphonates and denosumab, in patients with primary breast cancer receiving adjuvant endocrine therapy, aiming for better bone protection and\/or improving survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To summarize the clinical effects of antiresorptive agents in patients with early breast cancer receiving endocrine therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We systematically reviewed and synthesized the clinical benefits and harms of antiresorptive agents in patients with early breast cancer receiving endocrine therapy by calculating the risk ratios (RRs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the pooled meta-analysis, antiresorptive agents had significant clinical benefits on disease recurrence (RR 0.78, 95% CI 0.67-0.90) and locoregional recurrence (RR 0.69, 95% CI 0.49-0.95) in patients with breast cancer receiving endocrine therapy. Early use of antiresorptive agents has a beneficial effect on secondary endocrine therapy resistance instead of primary resistance. Safety analysis revealed that potential risk for osteonecrosis of the jaw (ONJ, RR 3.29, 95% CI 1.12-9.68) with antiresorptive agents; however, there is an insignificant difference in arthralgia. The subgroup analyses revealed that intervention with bisphosphonates might have profound clinical benefits, but also increased the occurrence of ONJ. A network meta-analysis further supported the clinical effects of early antiresorptive agent use compared with delayed use or placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Using antiresorptive agents early in patients with breast cancer receiving adjuvant endocrine therapy may provide additional benefits in risk reduction of recurrence, but there is a potential risk of ONJ.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad247","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T08:23:30Z","timestamp":1683879810000},"page":"e1433-e1447","source":"Crossref","is-referenced-by-count":5,"title":["The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis"],"prefix":"10.1210","volume":"108","author":[{"given":"Sheng-Fan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"},{"name":"Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University , Taipei 112, Taiwan, R.O.C"},{"name":"Department and Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University , Taipei 112, Taiwan, R.O.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Sheng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"},{"name":"Department and Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University , Taipei 112, Taiwan, R.O.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Yu","family":"Yeh","sequence":"additional","affiliation":[{"name":"Center for Evidence-based Medicine, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"},{"name":"Department of Medical Education, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh-Lih","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"},{"name":"Department and Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University , Taipei 112, Taiwan, R.O.C"},{"name":"Faculty of Pharmacy, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University , Taipei 112, Taiwan, R.O.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-1047","authenticated-orcid":false,"given":"Chern-En","family":"Chiang","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University School of Medicine , Taipei 112, Taiwan, R.O.C"},{"name":"General Clinical Research Center, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Huan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"},{"name":"School of Medicine, National Yang Ming Chiao Tung University School of Medicine , Taipei 112, Taiwan, R.O.C"},{"name":"Institute of Public Health and Community Medicine Research Center, National Yang Ming Chiao Tung University School of Medicine , Taipei 112, Taiwan, R.O.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Ming","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Surgery, Comprehensive Breast Health Center, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"},{"name":"Department of Surgery, School of Medicine, National Yang Ming Chiao Tung University , Taipei 112, Taiwan, R.O.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Chen","family":"Lee","sequence":"additional","affiliation":[{"name":"Department and Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University , Taipei 112, Taiwan, R.O.C"},{"name":"Faculty of Pharmacy, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University , Taipei 112, Taiwan, R.O.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2336-4731","authenticated-orcid":false,"given":"Chun-Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University School of Medicine , Taipei 112, Taiwan, R.O.C"},{"name":"Department of Surgery, Comprehensive Breast Health Center, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"},{"name":"Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"},{"name":"Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-6600","authenticated-orcid":false,"given":"Hao-Min","family":"Cheng","sequence":"additional","affiliation":[{"name":"Center for Evidence-based Medicine, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"},{"name":"Department of Medical Education, Taipei Veterans General Hospital , Taipei 112, Taiwan, R.O.C"},{"name":"School of Medicine, National Yang Ming Chiao Tung University School of Medicine , Taipei 112, Taiwan, R.O.C"},{"name":"Institute of Public Health and Community Medicine Research Center, National Yang Ming Chiao Tung University School of Medicine , Taipei 112, Taiwan, R.O.C"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"5","key":"2023101816063657600_dgad247-B1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/dc.2840080508","article-title":"Estrogen and progesterone receptors in cytology: a comprehensive review","volume":"8","author":"Masood","year":"1992","journal-title":"Diagn Cytopathol"},{"issue":"3","key":"2023101816063657600_dgad247-B2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v6.i3.231","article-title":"Current medical treatment of estrogen receptor-positive breast cancer","volume":"6","author":"Lumachi","year":"2015","journal-title":"World J Biol Chem"},{"issue":"11","key":"2023101816063657600_dgad247-B3","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00198-018-4642-2","article-title":"The tamoxifen paradox\u2014influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer","volume":"29","author":"Kyvernitakis","year":"2018","journal-title":"Osteoporos Int"},{"key":"2023101816063657600_dgad247-B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100254","article-title":"Incidence of fractures in young women with breast cancer\u2014a retrospective cohort study","volume":"18","author":"Stumpf","year":"2019","journal-title":"J Bone Oncol"},{"issue":"5","key":"2023101816063657600_dgad247-B5","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","article-title":"Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer","volume":"14","author":"Bines","year":"1996","journal-title":"J Clin Oncol"},{"issue":"5","key":"2023101816063657600_dgad247-B6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors: results from the Women\u2019s Health Initiative observational study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Intern Med"},{"issue":"3","key":"2023101816063657600_dgad247-B7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/gme.0b013e31804c793d","article-title":"Effect of early menopause on bone mineral density and fractures","volume":"14","author":"Gallagher","year":"2007","journal-title":"Menopause"},{"issue":"7","key":"2023101816063657600_dgad247-B8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1471-0528.2012.03324.x","article-title":"Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women","volume":"119","author":"Svejme","year":"2012","journal-title":"BJOG"},{"issue":"1","key":"2023101816063657600_dgad247-B9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","volume":"69","author":"Hadji","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"2023101816063657600_dgad247-B10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"issue":"9992","key":"2023101816063657600_dgad247-B11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"2023101816063657600_dgad247-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"issue":"10001","key":"2023101816063657600_dgad247-B13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"2023101816063657600_dgad247-B14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"2023101816063657600_dgad247-B15","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"2023101816063657600_dgad247-B16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.21.02647","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update","volume":"40","author":"Eisen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023101816063657600_dgad247-B17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"issue":"47","key":"2023101816063657600_dgad247-B18","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/sj.onc.1206937","article-title":"Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling","volume":"22","author":"Clarke","year":"2003","journal-title":"Oncogene"},{"issue":"18","key":"2023101816063657600_dgad247-B19","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jnci\/djj357","article-title":"Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis","volume":"98","author":"Mauri","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2023101816063657600_dgad247-B20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrc3920","article-title":"Mechanisms of aromatase inhibitor resistance","volume":"15","author":"Ma","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2023101816063657600_dgad247-B21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2021.09.043","article-title":"Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS\/calcium up-regulated amphiregulin-estrogen receptor loop signaling","volume":"523","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"key":"2023101816063657600_dgad247-B22","article-title":"Data from: The clinical benefits of antiresorptive agents in primary breast cancer patients receiving adjuvant endocrine therapy: a systematic review with pairwise and network meta-analysis","author":"Wang","journal-title":"Mendeley Data"},{"key":"2023101816063657600_dgad247-B23","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"2023101816063657600_dgad247-B24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","article-title":"Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial","volume":"12","author":"Llombart","year":"2012","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"2023101816063657600_dgad247-B25","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"2023101816063657600_dgad247-B26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"2023101816063657600_dgad247-B27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2023101816063657600_dgad247-B28","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2023101816063657600_dgad247-B29","author":"Harrer","year":"2019"},{"issue":"4","key":"2023101816063657600_dgad247-B30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"2","key":"2023101816063657600_dgad247-B31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"2023101816063657600_dgad247-B32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.004","article-title":"Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial","volume":"118","author":"Perrone","year":"2019","journal-title":"Eur J Cancer"},{"issue":"25","key":"2023101816063657600_dgad247-B33","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1200\/JCO.21.00311","article-title":"Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer (BOOG 2006-04): randomized phase III TEAM-IIB trial","volume":"40","author":"Vliek","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023101816063657600_dgad247-B34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"2023101816063657600_dgad247-B35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"issue":"11","key":"2023101816063657600_dgad247-B36","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"issue":"10","key":"2023101816063657600_dgad247-B37","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O\u2019Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2023101816063657600_dgad247-B38","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"2023101816063657600_dgad247-B39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"issue":"11","key":"2023101816063657600_dgad247-B40","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/annonc\/mds169","article-title":"The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis","volume":"23","author":"Hadji","year":"2012","journal-title":"Ann Oncol"},{"issue":"15","key":"2023101816063657600_dgad247-B41","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2023101816063657600_dgad247-B42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2023101816063657600_dgad247-B43","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3","author":"Bui","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2023101816063657600_dgad247-B44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"2023101816063657600_dgad247-B45","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"},{"issue":"5","key":"2023101816063657600_dgad247-B46","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jbspin.2019.07.005","article-title":"French Recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies","volume":"86","author":"Bouvard","year":"2019","journal-title":"Joint Bone Spine"},{"issue":"5","key":"2023101816063657600_dgad247-B47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anti-tumour activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"2023101816063657600_dgad247-B48","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","article-title":"Bisphosphonates induce breast cancer cell death in vitro","volume":"15","author":"Fromigue","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2023101816063657600_dgad247-B49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13058-017-0815-8","article-title":"Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells","volume":"19","author":"Ubellacker","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2023101816063657600_dgad247-B50","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12885-019-5379-9","article-title":"Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cancer"},{"issue":"11","key":"2023101816063657600_dgad247-B51","doi-asserted-by":"crossref","first-page":"8648","DOI":"10.18632\/oncotarget.3257","article-title":"Basal and therapy-driven hypoxia-inducible factor-1alpha confers resistance to endocrine therapy in estrogen receptor-positive breast cancer","volume":"6","author":"Jia","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"2023101816063657600_dgad247-B52","first-page":"5470","article-title":"Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK\/HIF-1 pathway inhibition in vivo","volume":"17","author":"Jia","year":"2018","journal-title":"Mol Med Rep"},{"issue":"22","key":"2023101816063657600_dgad247-B53","doi-asserted-by":"crossref","first-page":"10327","DOI":"10.1111\/jcmm.16946","article-title":"Prolactin and endocrine therapy resistance in breast cancer: the next potential hope for breast cancer treatment","volume":"25","author":"Li","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"18","key":"2023101816063657600_dgad247-B54","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care Ontario and American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023101816063657600_dgad247-B55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-20-2737","article-title":"Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR(+) early-stage breast cancer for 10 years of endocrine therapy","volume":"27","author":"Noordhoek","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2023101816063657600_dgad247-B56","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/jamaoncol.2021.1854","article-title":"Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial","volume":"7","author":"Friedl","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"2023101816063657600_dgad247-B57","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s00520-020-05748-8","article-title":"Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)","volume":"29","author":"Kizub","year":"2021","journal-title":"Support Care Cancer"},{"key":"2023101816063657600_dgad247-B58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100355","article-title":"Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer","volume":"28","author":"Waqas","year":"2021","journal-title":"J Bone Oncol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad247\/50521303\/dgad247.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/11\/e1433\/52218077\/dgad247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/11\/e1433\/52218077\/dgad247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T16:13:22Z","timestamp":1697645602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/11\/e1433\/7160561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,5,12]]},"published-print":{"date-parts":[[2023,10,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad247","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,5,12]]}}}